Quick Answer
ADIAL PHARMACEUTICALS, INC. reported Earnings Per Share Diluted of $11.93 (loss) per share for the year ending 2025.
- ADIAL PHARMACEUTICALS, INC. showed an increase of +82.5% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from ADIAL PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $0.25 (loss) per share | Q3 2021: $0.22 (loss) per share | Q1 2022: $0.13 (loss) per share | Q2 2022: $3.96 (loss) per share | Q3 2022: $3.02 (loss) per share | Q1 2023: $2.75 (loss) per share | Q2 2023: $0.96 per share | Q3 2023: $1.18 (loss) per share | Q1 2024: $2.19 (loss) per share | Q2 2024: $0.59 (loss) per share | Q3 2024: $0.38 (loss) per share | Q1 2025: $0.34 (loss) per share | Q2 2025: $0.18 (loss) per share | Q3 2025: $0.08 (loss) per share.
- Over the full 5 years of available data (2021 to 2025), ADIAL PHARMACEUTICALS, INC.'s Earnings Per Share Diluted has declined by 1,047.1%.
- Historical annual values: Fiscal year 2025: $11.93 (loss) per share | Fiscal year 2024: $68.01 (loss) per share | Fiscal year 2023: $3.60 (loss) per share | Fiscal year 2022: $12.71 (loss) per share | Fiscal year 2021: $1.04 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: